EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019

Greta Bushnell iD, Kristen Lloyd, Mark Olfson, Tobias Gerhard, Katherine Keyes, Magdalena Cerdá iD, Deborah Hasin iD

Addiction · 2025

DOI: 10.1111/add.16749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction, 2025. Verfasst von Greta Bushnell und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Medicaid, Hypnotics and Sedatives, Anti-Anxiety Agents, Substance-Related Disorders. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Sedative, hypnotic or anxiolytic use disorders (SHA‐UD) are defined by significant impairment or distress caused by recurrent sedative, hypnotic or anxiolytic use. This study aimed to measure trends in the prevalence of SHA‐UD diagnoses in adolescent and young adult US Medicaid enrollees from 2001 to 2019.

Design

Annual, cross‐sectional study, 2001–2019.

Setting

Medicaid Analytic eXtracts (MAX) and Transformed Medicaid Analytic Files (TAF) from 42 US states with complete data. Participants/Cases Adolescents (13–17 years) and young adults (18–29 years) with ≥10 months Medicaid enrollment in the calendar year; analytic sample contained 5.7 (2001) to 13.2 (2019) million persons per year.

Measurements

Annual prevalence of SHA‐UD in adolescent and young adult Medicaid enrollees [defined as an inpatient or outpatient ICD code (304.1x, 305.4x, F13.1x, F13.2x) in the calendar year] was stratified by sex, race/ethnicity, receipt of a benzodiazepine, z‐hypnotic or barbiturate prescription, and selected mental health diagnoses. Absolute and relative percent‐changes from 2001 vs. 2019 were summarized. Secondary analyses were restricted to states with more consistent data capture.

Findings

The prevalence of SHA‐UD diagnoses statistically significantly increased for adolescents (0.01% to 0.04%) and young adults (0.05% to 0.24%) from 2001 to 2019. Increasing trends were observed in sex and race/ethnicity subgroups, with greatest relative increases among Non‐Hispanic Black (624%) and Hispanic (529%) young adults. The trend increased among those with and without a benzodiazepine, z‐hypnotic or barbiturate prescription; i.e. young adults with (2001 = 0.39% to 2019 = 1.77%) and without (2001 = 0.03% to 2019 = 0.18%) a prescription. Most adolescents (76%) and young adults (91%) with a SHA‐UD diagnosis in 2019 had a comorbid substance use disorder.

Conclusions

Sedative, hypnotic or anxiolytic use disorders (SHA‐UD) diagnoses increased 3‐ to 5‐fold between 2001 and 2019 for adolescent and young adult US Medicaid enrollees, with prevalence remaining low in adolescents. The increase over two decades may be attributed to changes in the availability, use and misuse of sedative, hypnotic and anxiolytic medications and to increased detection, awareness and diagnosing of SHA‐UD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicaidHypnotics and SedativesAnti-Anxiety AgentsSubstance-Related DisordersHumansAdolescentUnited StatesMaleYoung AdultFemaleCross-Sectional StudiesAdultPrevalence

Stichwörter der Autor:innen

adolescentanti‐anxiety agentsbenzodiazepinehypnotics and anxiolytic use disorderhypnotics and sedativessedativesubstance‐related disordersyoung adult

Substanzen

Hypnotics and SedativesAnti-Anxiety Agents

Autor:innen und Institutionen

  • Center for Pharmacoepidemiology and Treatment Science, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, USA.
  • Department of Biostatistics and Epidemiology, Rutgers University School of Public Health, Piscataway, NJ, USA.
  • Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA.
  • Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
  • Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, USA.
  • Center for Opioid Epidemiology and Policy, Department of Population Health, New York University School of Medicine, New York, NY, USA.

ORCID-Profile: Greta Bushnell, Magdalena Cerdá, Deborah Hasin

Förderung

  • NIDA NIH HHS
  • National Institute on Drug Abuse

Zitieren

APA

Bushnell, G., Lloyd, K., Olfson, M., Gerhard, T., Keyes, K., Cerdá, M., & Hasin, D. (2025). Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019. Addiction. https://doi.org/10.1111/add.16749

Vancouver

Bushnell G, Lloyd K, Olfson M, Gerhard T, Keyes K, Cerdá M, et al. Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019. Addiction. 2025. doi:10.1111/add.16749

BibTeX
@article{Bushnell2025,
  author = {Bushnell, Greta and Lloyd, Kristen and Olfson, Mark and Gerhard, Tobias and Keyes, Katherine and Cerdá, Magdalena and Hasin, Deborah},
  title = {Nationwide trends in diagnosed sedative, hypnotic or anxiolytic use disorders in adolescents and young adults enrolled in Medicaid: 2001–2019},
  journal = {Addiction},
  year = {2025},
  doi = {10.1111/add.16749}
}
Kostenlos starten →